Pharmaceutical Fill and Finish Outsourcing Market is expected to reach US$ 4,010.51 million by 2028

Liquids Segment to Grow at Highest CAGR During 2021–2028

According to our latest study on “Pharmaceutical Fill and Finish Outsourcing Market Size and Forecast to 2028 – COVID-19 Impact and Global Analysis – by State of Finished Product and Content,” and Geography. The market is projected to reach US$ 4,010.51 million by 2028 from US$ 2,657.04 million in 2021; it is expected to grow at a CAGR of 6.1% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.       

Based on state of finished product, the pharmaceutical fill and finish outsourcing market is segmented into solids, semi-solids, and liquids. The liquids segment is likely to account for a large market share during 2021–2028.

By content, the pharmaceutical fill and finish outsourcing market is segmented into organic substances isolated from animal origin, organic substances isolated from microorganisms, and inorganic substances. The organic substances isolated from the microorganisms segment held a considerable share of the market in 2021 and is likely to continue its dominance in the market during the forecast period.  

The COVID-19 pandemic disrupted various trades and businesses worldwide. Several regions such as North America, Europe, and RoW experienced an economic downturn dramatically. However, the pandemic also offered lucrative opportunities for the pharmaceutical and biopharmaceutical companies to strengthen their research and development. For instance, accelerating demand for new treatments for COVID-19 or other much-needed medicines requires high volume capacity production. Therefore, many pharmaceutical companies approach sponsor partners such as contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs) for scaling their production and fulfilling capacity demands at commercial levels. Additionally, with rising price levels of raw materials, pharmaceutical companies approach CMOS for benefits such as meeting short-level demand arising from the market and addressing offshore supply issues. Such factors have a positive impact on the market growth during the analysis period from 2021 to 2028.

Abbott, Teva Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries Ltd, Piramal Enterprises Ltd, MabPlex International Ltd, Wockhardt, Cytovance Biologics, Thermo Fischer Scientific Inc. (Patheon N.V.), and Boehringer Ingelheim International GmbH are among the leading companies operating in the pharmaceutical fill and finish outsourcing market.    

Pharmaceutical Fill and Finish Outsourcing Market, by Region, 2021 (%)

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com